EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Xeris Biopharma Holdings, Inc. (XERS) had EBITDA of $12.02M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$83.13M
Net Income	$2.23M
Cost of Goods Sold	$10.57M
Gross Profit	$72.55M
Operating Expenses	$75.21M
Operating Income	$7.92M
Non-Operating Income/Expense	$-5.68M
Pre-Tax Income	$2.23M
Normalized Pre-Tax Income	$2.23M
Income after Taxes	$2.23M
Income from Continuous Operations	$2.23M
Consolidated Net Income/Loss	$2.23M
Normalized Income after Taxes	$2.23M
EBIT	$7.92M
EBITDA	$12.02M
Weighted-Average Shares Outstanding (Basic)	170.52M
Weighted-Average Shares Outstanding (Diluted)	177.63M
Earnings per Share (EPS) (Basic)	$0.01
Earnings per Share (EPS) (Diluted)	$0.01
Balance Sheet Financials
Current Assets	$251.68M
Property, Plant, and Equipment	$5.03M
Long-Term Assets	$140.33M
Total Assets	$392.01M
Current Liabilities	$118.59M
Long-Term Debt	$221.22M
Long-Term Liabilities	$260.41M
Total Liabilities	$379.00M
Common Equity	$13.01M
Tangible Shareholders Equity	$-95.22M
Shareholders Equity	$13.01M
Common Shares Outstanding	172.56M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$9.87M
Cash Flow from Investing Activities	$-0.33M
Cash Flow from Financial Activities	$-8.84M
Beginning Cash	$115.06M
End Cash	$115.77M
Increase/Decrease in Cash	$0.71M
Stock-Based Compensation	$4.14M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.12
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.94
Debt to Equity Ratio	17.00
Gross Margin	87.28%
Operating Margin	9.52%
EBIT Margin	9.52%
EBITDA Margin	--
Pre-Tax Profit Margin	2.69%
Profit Margin	2.69%
Free Cash Flow	$9.54M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.21
Inventory Turnover	0.14
Receiveable Turnover	1.48
Days Sales in Receivables	60.95
Return on Equity	17.17%
Return on Tangible Equity	-2.35%
Return on Assets	0.57%
Return on Investments	0.95%
Book Value Per Share	$0.08
Free Cash Flow per Share	$0.05
Operating Cash Flow per Share	$0.06

Data from Zacks Investment Research, Inc.